We are live on ! Find out more
BMRN icon

BioMarin Pharmaceuticals
BMRN

388 hedge funds and large institutions have $16.9B invested in BioMarin Pharmaceuticals in 2015 Q4 according to their latest regulatory filings, with 50 funds opening new positions, 150 increasing their positions, 141 reducing their positions, and 52 closing their positions.

New
Increased
Maintained
Reduced
Closed

25% more call options, than puts

Call options by funds: $249M | Put options by funds: $199M

6% more repeat investments, than reductions

Existing positions increased: 150 | Existing positions reduced: 141

1% more capital invested

Capital invested by funds: $16.8B → $16.9B (+$121M)

4% less first-time investments, than exits

New positions opened: 50 | Existing positions closed: 52

1% less funds holding

Funds holding: 393 → 388 (-5)

36% less funds holding in top 10

Funds holding in top 10: 14 → 9 (-5)

Holders
388
Holders Change
-5
Holders Change %
-1.27%
% of All Funds
10.18%
Holding in Top 10
9
Holding in Top 10 Change
-5
Holding in Top 10 Change %
-35.71%
% of All Funds
0.24%
New
50
Increased
150
Reduced
141
Closed
52
Calls
$249M
Puts
$199M
Net Calls
+$49.4M
Net Calls Change
+$65.8M

Top Buyers

1
Jennison Associates
Jennison Associates
New York
+$182M
2
Winslow Capital Management
Winslow Capital Management
Minnesota
+$166M
3
Wells Fargo
Wells Fargo
California
+$104M
4
Temasek Holdings
Temasek Holdings
Singapore
+$92.8M
5
Goldman Sachs
Goldman Sachs
New York
+$70.1M

Top Sellers

1
Fidelity Investments
Fidelity Investments
Massachusetts
-$207M
2
Capital Research Global Investors
Capital Research Global Investors
California
-$99.4M
3
AC
Amici Capital
New York
-$48.1M
4
RG
Redmile Group
California
-$38.8M
5
Citadel Advisors
Citadel Advisors
Florida
-$36.9M
Name Holding Trade Value Shares
Change 		Change in
Stake
Capital Research Global Investors
1
Capital Research Global Investors
California
$1.88B -$99.4M -952,119 -5%
Fidelity Investments
2
Fidelity Investments
Massachusetts
$1.53B -$207M -1,979,702 -12%
Sands Capital Management
3
Sands Capital Management
Virginia
$1.22B +$25.2M +241,600 +2%
Vanguard Group
4
Vanguard Group
Pennsylvania
$1.17B +$37.1M +355,727 +3%
T. Rowe Price Associates
5
T. Rowe Price Associates
Maryland
$841M +$51.3M +491,119 +7%
Primecap Management
6
Primecap Management
California
$768M -$3.59M -34,350 -0.5%
Jennison Associates
7
Jennison Associates
New York
$701M +$182M +1,739,328 +35%
JP Morgan Chase
8
JP Morgan Chase
New York
$590M +$49.3M +472,390 +9%
BBA
9
Baker Bros. Advisors
New York
$431M +$4.04M +38,730 +1%
BIT
10
BlackRock Institutional Trust
California
$401M +$1.87M +17,925 +0.5%
BFA
11
BlackRock Fund Advisors
California
$366M -$36.1M -345,791 -9%
Temasek Holdings
12
Temasek Holdings
Singapore
$364M +$92.8M +888,545 +34%
State Street
13
State Street
Massachusetts
$326M +$426K +4,083 +0.1%
Invesco
14
Invesco
Georgia
$277M +$18.3M +175,626 +7%
Wells Fargo
15
Wells Fargo
California
$272M +$104M +991,740 +62%
O
16
OppenheimerFunds
New York
$180M -$12.5M -120,150 -7%
TCIM
17
TIAA CREF Investment Management
New York
$167M +$11.6M +111,026 +7%
Winslow Capital Management
18
Winslow Capital Management
Minnesota
$166M +$166M +1,585,521 New
BRC
19
Blue Ridge Capital
New York
$161M – – –
Franklin Resources
20
Franklin Resources
California
$155M +$7.67M +73,450 +5%
SAM
21
Sectoral Asset Management
Quebec, Canada
$142M +$40.7M +390,099 +40%
PAI
22
Palo Alto Investors
California
$140M -$34.4M -329,645 -20%
Victory Capital Management
23
Victory Capital Management
Texas
$140M +$708K +6,782 +0.5%
TG
24
TCW Group
California
$125M +$23.9M +228,796 +24%
First Trust Advisors
25
First Trust Advisors
Illinois
$123M -$30.9M -295,520 -20%
1
2 3 4 5

BMRN Hedge Fund Activity: Q4 2015 in Review

388 of the 3,812 institutional investors tracked by Wall St. Rank reported a position in BioMarin Pharmaceuticals (BMRN) for Q4 2015, worth a combined $16.9B — up 0.72% from $16.8B a quarter earlier.

Sellers outnumbered buyers: 52 funds closed out of BMRN and 50 opened new positions — a net loss of 2 holders — while 141 trimmed existing stakes and 150 added.

The largest buyer was Jennison Associates, adding an estimated $182M. The largest seller was Fidelity Investments, cutting an estimated $207M.

  • 388 institutional investors held BioMarin Pharmaceuticals (BMRN) as of Q4 2015, down from 393 in Q3 2015.
  • Funds reported $16.9B of BioMarin Pharmaceuticals stock for Q4 2015, up 0.72% quarter-over-quarter.
  • 50 funds opened new BioMarin Pharmaceuticals positions in Q4 2015 and 52 closed out, a net change of -2 holders.
  • The largest BioMarin Pharmaceuticals buyer in Q4 2015 was Jennison Associates, an estimated $182M added.
  • The largest BioMarin Pharmaceuticals seller in Q4 2015 was Fidelity Investments, an estimated $207M sold.

Based on aggregated 13F filings for Q4 2015.